For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and the formulated version represents a significant advancement . These groundbreaking therapies preserve the transthyretin protein, halting its damaging build-up and reduci